Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2010 · Analytical study · PMID 20675162
Explore the library
Preclinical evidenceModified long-acting IGF-1 analog
IGF-1 LR3
IGF-1 LR3 is a modified insulin-like growth factor analog used in experimental research. It is not interchangeable with native IGF-1 or the approved medication mecasermin.
Also indexed as: Long-R3 IGF-1
A clear starting point
IGF-1 LR3 is a modified insulin-like growth factor analog used in experimental research. It is not interchangeable with native IGF-1 or the approved medication mecasermin.
Systems mapping shows biological relevance, not a treatment recommendation or a patient CPI score.
No validated chemical structure is displayed in this edition.
How it works
IGF-1 receptor signaling
IGF-1 LR3 is a modified insulin-like growth factor analog used in experimental research. It is not interchangeable with native IGF-1 or the approved medication mecasermin.
- Targets & processes
- IGF-1 receptor signaling
- Systems & tissues
- See the pathway description; category links describe research relevance, not demonstrated treatment effects.
What does the evidence show?
Growth-factor signaling in cell culture and animal models.
What this does not establish
Animal organ-growth research and analytical identification of a product are not clinical efficacy trials. LR3 is not mecasermin, an approved IGF-1 medication.
The Journal of endocrinology · 1995 · Cell / animal study · PMID 7561636
Citation metadata from PubMed, a service of the U.S. National Library of Medicine, NIH. A citation match is not a guarantee of study quality. Abstracts are not full-text reviews.
Safety is a separate question
IGF signaling can affect glucose and growth pathways; hypoglycemia and unintended tissue growth are concerns. Human safety for this analog is not established.
Contraindications & cautions
Not an exhaustive contraindication review. IGF signaling can affect glucose and growth pathways; hypoglycemia and unintended tissue growth are concerns. Human safety for this analog is not established.
Medication & supplement interactions
Interaction information is incomplete. IGF signaling can affect glucose and growth pathways; hypoglycemia and unintended tissue growth are concerns. Human safety for this analog is not established.
Regulatory status · United States
Not FDA-approved. No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
This is not an exhaustive safety list. Regulatory status varies by jurisdiction and product; investigational use is not approval.
Make the science interactive
A dedicated lesson has not been published for this ingredient yet. Explore the cited profile or ask the instructor.
Your scientific classroom
Ask the IW Science Instructor
Basic level · Published sources only · AI evidence check
Ask about general science. Do not enter names, personal health details or medication lists. This is not a clinical consultation. Discussion stays in this browser’s private learning session for up to 90 days.
All medications and therapies discussed are for educational purposes only. Prescriptions are determined independently by the licensed clinician following a medical evaluation. There is no guarantee that any medication or peptide will be prescribed.
IW Interactive Learning Engine · Adapted from stable OpenMAIC v1.2.1. Open-source license
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.